Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Prostate Cancer Undergoing Hormone Therapy

Is use of antidiabetic agent sodium-glucose cotransporter 2 (SGLT2) inhibitors associated with clinical outcomes in patients with prostate cancer undergoing hormone therapy?In this cohort study with a target trial emulation design including 14 223 patients with prostate cancer, SGLT2 inhibitor use was associated with considerably lower risks of androgen deprivation therapy failure and lower risk of next-generation hormonal agent failure.SGLT2 inhibitors may delay disease progression in patients with prostate cancer receiving hormone therapy, suggesting their potential role as adjuncts to hormonal therapy in the treatment of prostate cancer.

Corresponding Author: Rong Na, MD, PhD, MPH, Division of Urology, Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, 102 Pokfulam Rd, Hong Kong 999077, China (yungna@hku.hk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.